• 1
    Ball DW BS, DeBustos AC. Thyroid. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
  • 2
    Harris PE. The management of thyroid cancer in adults: a review of new guidelines. Clin Med. 2002; 2: 144146.
  • 3
    Kendall-Taylor P, Working Group. Guidelines for the management of thyroid cancer. Clin Endocrinol. 2003; 58: 400402.
  • 4
    National Comprehensive Cancer Network. Practice guidelines in oncology/thyroid carcinoma. Available at URL:
  • 5
    Franc S, Niccoli-Sire P, Cohen R, et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2001; 55: 403409.
  • 6
    Chen H, Roberts JR, Ball DW, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg. 1998; 227: 887895.
  • 7
    Kebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg. 2005; 200: 890896.
  • 8
    Raue F, Kotzerke J, Reinwein D, et al. Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest. 1993; 71: 712.
  • 9
    Bergholm U, Adami HO, Bergstrom R, Backdahl M, Akerstrom G. Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group. Acta Chir Scand. 1990; 156: 3746.
  • 10
    Kameyama K, Takami H. Medullary thyroid carcinoma: nationwide Japanese survey of 634 cases in 1996 and 271 cases in 2002. Endocr J. 2004; 51: 453456.
  • 11
    Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000; 88: 11391148.
  • 12
    Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer. 1997; 79: 564573.
  • 13
    National Cancer Institute D, Survillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) program ( SEER* Stat Database: Incidence — SEER 13 Regs Public-Use, 2004 Sub (1973–2002). Available at URL:, released April 2005, based on the November 2004 submission.
  • 14
    National Cancer Institute D, Survillance Research Program, Cancer Statistics Branch. Available at URL: [Accessed May 2005].
  • 15
    GreeneFL PD, FlemingID, et al., editors. American Joint Committee on Cancer Staging Manual. 6th ed. Philadelphia: JB Lippincott; 1997.
  • 16
    Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf). 1998; 48: 265273.
  • 17
    Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see Comments]. Cancer. 1998; 83: 26382648.
  • 18
    Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003; 88: 20702075.
  • 19
    Tramagnini P, Iacobone M, Sebag F, Marcy M, DeMicco C, Henry JF. Lymph node involvement in macroscopic medullary thyroid carcinoma. Br J Surg. 2005; 92: 449453.
  • 20
    Miyauchi A, Matsuzuka F, Hirai K, et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg. 2002; 26: 10231028.
  • 21
    Dralle H, Scollo Damm I, Scheumann GF, Kotzerke J, Kupsch E. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method. Henry Ford Hosp Med J. 1992; 40: 264267.
  • 22
    Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999; 229: 880887.
  • 23
    Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H. Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg. 2004; 28: 12711274.
  • 24
    van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg. 1990; 212: 395400; discussion 400–391.
  • 25
    Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 1984; 63: 319342.
  • 26
    Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer. 2000; 83: 715718.
  • 27
    Juweid ME, Hajjar G, Stein R, et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med. 2000; 41: 93103.
  • 28
    Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998; 228: 320330.